More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

From a more pessimistic macroeconomic view, to uncertainty arising from ongoing trade conflicts, and geopolitical tensions, executives weigh in on key issues that will impact performance in 2020. Taking the pulse To gain a perspective on what is...

The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents research-based innovator companies, put out a position paper on how to best address drug shortages. This follows reports by both the European Medicines...

With 2020 underway, what are key developments and trends in the pharmaceutical industry that are on the industry's radar for this year? DCAT Value Chain Insights provides its Top 10 Pharma Watch List for 2020. The Top 10 Pharma Watch List for...

The stars are aligned for another strong year of performance for CDMOs. DCAT Value Chain Insights examines industry fundamentals and an outlook for pharma outsourcing in 2020. Strong fundamentals but some risks 2019 proved to be a stellar year...

The FDA approved 48 new molecular entities in 2019, below the 59 NME approvals in 2018, a recent record high, but still the third highest number of approvals since 1996, when 53 NMEs were approved. Which companies and drugs scored FDA...

What are the key market developments in the pharmaceutical industry to watch for in 2020? DCAT Value Chain Insights highlights products projected for high growth prospects, important R&D projects, and overall market growth. Products to watch...

To extract continuous value from R&D activities and ensure manufacturing quality, pharmaceutical companies are – or should be – embracing digital transformation. This business journey uses technology to turn fragmented systems into a harmonized...

What key trends or issues emerged in 2019 that are positioned to be on the industry’s radar in 2020? DCAT Value Chain Insights provides a Top 10 ranking. Top 10 Developments from 2019 for the Industry Radar in 2020 1. Drug-pricing reform in the...